Monday, July 13, 2026

Neuroprotective BL1107 Misses Primary Endpoint in Glaucoma

The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller phase 1/2a study following 28 days of topical administration for glaucoma.

Monday, July 13, 2026

Glaucoma Neuroprotective Candidate Misses Primary Endpoint

The Bausch + Lomb study did not meet its primary endpoint, defined as change from baseline in visual field mean deviation at day 28 (exit, hour 2).

Friday, July 10, 2026

FDA Recalls More Than 2.5 Million Bottles of Eye Drops

Prednisolone acetate ophthalmic suspension, USP, 1%, manufactured by Lupin Limited, has been recalled due to the presence of a foreign substance.

Thursday, June 25, 2026

GLK-321 Study Completes Phase 2 Enrollment

Glaukos is evaluating its iLution platform in patients with Demodex blepharitis.

Tuesday, June 23, 2026

Bayer Expands Glaucoma Pipeline With PER-001

The acquisition of Perfuse Therapeutics adds an investigational phase 2 implant to Bayer's ophthalmology portfolio.

Tuesday, June 23, 2026

Envision Health Technologies Partners with Zeiss on VR-Based Glaucoma Testing.

The collaboration aims to advance visual function assessment through virtual reality technology and software-driven innovation. 

Wednesday, June 17, 2026

Thea Launches Zolymbus Preservative-Free Gel for Glaucoma Management

Zolymbus (bimatoprost ophthalmic gel) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Monday, May 18, 2026

Category III Code Issued for BIM-IOL Implant

SpyGlass Pharma’s drug-eluting IOL implant receives a Category III code; phase 3 trials continue enrollment.

Tuesday, May 12, 2026

FDA Clears Wireless Pressure Goggles for Glaucoma

The connected system enables remote monitoring of overnight patient adherence.

Wednesday, May 6, 2026

Bayer Secures PER-001 Through Perfuse Deal

The sustained-release intraocular implant program focuses on visual field preservation and ischemia-related damage.

Tuesday, March 31, 2026

Amaros Backs New Network for Glaucoma Innovation

The Interventional Glaucoma Network will integrate clinical data to accelerate research, enrollment, and outcomes tracking.

Tuesday, March 31, 2026

Iantrek Expands Allo Platform With AlloSpan Canal

The system is designed to provide durable canal support without permanent synthetic implants.

Thursday, March 26, 2026

Trial Supports Reduced Drop Volume for Glaucoma Treatment

Smaller drops were associated with improved pressure control and fewer adverse effects.

Monday, March 23, 2026

Elios Laser Trial Meets Endpoints at 24 Months

Data from the pivotal US study shows significant IOP reduction and consistent safety for the excimer laser procedure.

Friday, March 13, 2026

Nanodropper Launches Eye Drop Score Quiz

New online tool aims to improve patient understanding of eyedrop use and adherence.

Thursday, March 12, 2026

FDA Approves Tecnis PureSee IOL

Johnson & Johnson’s EDOF lens aims to expand visual range while maintaining contrast sensitivity.

Wednesday, March 11, 2026

Virtual Field Rebrands as Carrot

The new brand reflects the company’s expansion beyond visual field testing to a broader diagnostic platform with integrated clinical workflows.

Tuesday, March 10, 2026

SpyGlass Reports 12-Month Results for BIM-IOL System

Data from the phase 1/2 trial demonstrate sustained IOP reduction and preserved visual acuity in OAG and OHT patients.

Tuesday, February 10, 2026

Finevision HP IOL Makes US Clinical Debut

BVI announces the first US implantations of the presbyopia-correcting trifocal IOL following FDA clearance last fall.

Tuesday, February 3, 2026

New Zeiss Microscopes Cleared in China

NMPA clearance expands access to advanced ophthalmic visualization platforms.

Wednesday, January 28, 2026

FDA Allows Repeat Administration of iDose TR

Updated labeling permits re-administration of the intracameral travoprost implant under a defined treatment protocol.

Monday, January 26, 2026

Clinical Trial Begins for Calibreye System

The first patient has been enrolled in the ADAPT trial, which will assess the safety and effectiveness of a titratable shunt for IOP control.

Friday, January 23, 2026

SpyGlass Begins Phase 3 Trials for Drug-Eluting IOL

A pair of registrational trials will compare the company’s bimatoprost-eluting lens to a standard lens plus drops.

Tuesday, January 13, 2026

Topcon Announces Remote Monitoring Deal With RemoniHealth

The platform is designed to support continuous glaucoma surveillance using home-based testing and remote care management.